Correcting for discounting and loss aversion in composite time trade-off Health Economics Apr 26 Written by Matthijs Versteegh Quality of life Matthijs Versteegh Previous Previous Estimating Quality of Life Decrements in Oncology Using Time to Death Next Next Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020
Correcting for discounting and loss aversion in composite time trade-off Health Economics Apr 26 Written by Matthijs Versteegh Quality of life Matthijs Versteegh
